Form 4: Recursion CFO Ben Taylor Executes Tax Withholding Sale

Recursion Pharmaceuticals CFO Ben Taylor disposed of 25,018 shares to satisfy tax obligations related to restricted stock units.

Summary

• Ben R. Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc. (RXRX), reported a transaction involving the disposal of 25,018 shares of Class A Common Stock.
• The transaction occurred on May 15, 2026, at a price of $3.04 per share.
• The disposal was a mandatory tax withholding event related to the net settlement of restricted stock units (RSUs).
• Following this transaction, Mr. Taylor retains beneficial ownership of 1,107,272 shares of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax settlement rather than a discretionary change in investment position.

Positives

• The transaction was a routine administrative action to satisfy tax obligations rather than a discretionary market sale.
• The executive maintains a significant equity stake of 1,107,272 shares, aligning his interests with shareholders.

Negatives

• The transaction resulted in a reduction of the executive's direct share ownership.

Risks

• None identified; this is a standard regulatory disclosure for tax withholding.

Future Outlook

Not applicable as this is a retrospective disclosure of a completed transaction.

Industry Context

StockSavvy.ai notes that net settlement of RSUs is a standard industry practice for biotechnology executives to manage tax liabilities associated with equity-based compensation, and this filing does not signal a change in corporate strategy or executive confidence.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity compensation management.
• The retention of over 1.1 million shares by the CFO is consistent with long-term incentive structures seen in mid-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax settlement.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Form 4, Insider Trading, CFO, Tax Withholding, Equity Compensation